Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study.

Objective: To determine the long-term safety and efficacy of repeated intrathecal (IT) administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs) in patients with progressive MS by evaluating subjects 2 years after treatment.

Methods: Twenty subjects were enrolled as part of a phase I, open-label single-arm study of 3 IT injections of MSC-NPs spaced 3 months apart. Subjects were evaluated for adverse events and disability outcomes including the Expanded Disability Status Scale (EDSS) and the timed 25-foot walk (T25FW).

Safety of long-term intrathecal methotrexate in progressive forms of MS.

Background: There are few treatment options for multiple sclerosis (MS) patients with advanced disability [expanded disability status scale (EDSS) ⩾ 6.0]. In 2010, we reported initial results of using intrathecal methotrexate (ITMTX) in patients with progressive MS.

Spatiotemporal continuity implicated in the binding of features and object identity.

This study continues the work of Anes et al. (in preparation) in which manipulation of features incidental to an object elicited robust effects in a dynamic object recognition paradigm. In the current series, the spatiotemporal continuity of identity and feature presentation is increasingly distorted between experiments in an attempt to disrupt a process Triesman (1996) calls "binding" of an object's identity and features.